New research finds ginger counters certain autoimmune diseases in mice
(Michigan Medicine - University of Michigan) The main bioactive compound of ginger root lowers autoantibody production and helps halt disease progression in mice with antiphospholipid syndrome and lupus. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 6, 2021 Category: Biology Source Type: news
Developing new classification criteria for improving antiphospholipid syndrome research
(Hospital for Special Surgery) An international team of more than 80 collaborators led by Hospital for Special Surgery (HSS) investigators is developing new classification criteria for clinical research of antiphospholipid syndrome (APS), a life-threatening autoimmune clotting disorder. In a paper published online in Arthritis Care& Research, the investigators reported on the first two of four phases of criteria development. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2020 Category: International Medicine & Public Health Source Type: news
New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Scientists Have Uncovered the Likely Cause of a Serious COVID-19 Symptom: Blood Clotting
One of the more surprising symptoms of COVID-19 has been the blood clots that many patients, including younger ones, have experienced with the infection. The clots have in some cases led to dangerous blockages in the lungs, caused strokes and even death, even in people without a history of circulatory conditions.
In a paper published in Science earlier this week, researchers provide a glimpse into what may be driving the clots triggered by COVID-19 infection. The group found that a specific set of antibodies known as autoantibodies—which are rogue versions of cells meant to defend the body from pathogens, but instead...
Source: TIME: Health - November 5, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
New Target to Combat COVID-Related Thrombosis? New Target to Combat COVID-Related Thrombosis?
More than half of patients hospitalized with COVID-19 have prothrombotic antiphospholipid autoantibodies in their blood, which may trigger to blood clots, new research suggests.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 4, 2020 Category: Intensive Care Tags: Cardiology News Source Type: news
Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
'Hypercoagulation,' Antiphospholipid Antibodies Seen in COVID-19
Marked coagulopathy and presence of antiphospholipid antibodies and cerebral infarcts in patients with COVID-19 suggest the infection represents a 'hypercoagulable' state, experts write. (Source: WebMD Health)
Source: WebMD Health - April 15, 2020 Category: Consumer Health News Source Type: news
' Hypercoagulation,' Antiphospholipid Antibodies Seen in COVID-19'Hypercoagulation,' Antiphospholipid Antibodies Seen in COVID-19
Marked coagulopathy and presence of antiphospholipid antibodies and cerebral infarcts in patients with COVID-19 suggest the infection represents a ' hypercoagulable ' state, experts write.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 14, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
Rivaroxaban Misfires in Antiphospholipid Syndrome Rivaroxaban Misfires in Antiphospholipid Syndrome
Rivaroxaban not only failed to show noninferiority to warfarin, but trended toward higher thrombosis risk in patients with APS.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 17, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Study Compares Anticoagulants for Antiphospholipid Syndrome
TUESDAY, Oct. 15, 2019 -- In thrombotic antiphospholipid antibody syndrome (APS), rivaroxaban is not noninferior to dose-adjusted vitamin K antagonists (VKAs), according to a study published online Oct. 15 in the Annals of Internal Medicine.
Josep... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 15, 2019 Category: Pharmaceuticals Source Type: news
DAPT for Preventing Thrombosis in Antiphospholipid Syndrome DAPT for Preventing Thrombosis in Antiphospholipid Syndrome
Can dual antiplatelet therapy effectively prevent thrombosis recurrence in patients with antiphospholipid syndrome? How does it compare to warfarin?Rheumatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 4, 2019 Category: Allergy & Immunology Tags: Rheumatology Journal Article Source Type: news
How common gut bacteria trigger a lethal autoimmune disease
Antiphospholipid syndrome, an immune system disorder that raises the risk of blood clots, may be triggered by the common gut bactrium Roseburia intestinalis. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 18, 2019 Category: Universities & Medical Training Source Type: news
A probable case of catastrophic antiphospholipid syndrome: Should high-dose steroids be given in the setting of polymicrobial sepsis?
In this clinical vignette, we present a case of a 59-year-old woman with catastrophic antiphospholipid syndrome likely triggered by polymicrobial sepsis. The diagnostic criteria and clinical manifestations of catastrophic antiphospholipid syndrome are reviewed. We also compare diagnostic criteria and clinical manifestations with other clinical entities in the differential diagnosis, including thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome, disseminated intravascular coagulation, sepsis, and inflammatory bowel disease. Catastrophic antiphospholipid syndrome is a rare, but lethal condition, and treatm...
Source: Current Awareness Service for Health (CASH) - May 29, 2019 Category: Consumer Health News Source Type: news
